vs

Side-by-side financial comparison of Amalgamated Financial Corp. (AMAL) and Bioceres Crop Solutions Corp. (BIOX). Click either name above to swap in a different company.

Amalgamated Financial Corp. is the larger business by last-quarter revenue ($85.2M vs $77.6M, roughly 1.1× Bioceres Crop Solutions Corp.). On growth, Amalgamated Financial Corp. posted the faster year-over-year revenue change (9.4% vs -16.8%). Over the past eight quarters, Amalgamated Financial Corp.'s revenue compounded faster (4.3% CAGR vs -8.4%).

CI Financial is a Canadian investment management company based in Toronto, Ontario. It offers investment management and wealth management services targeted to high net worth retail investors, as well as brokerage and trading services to portfolio managers and institutional investors.

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

AMAL vs BIOX — Head-to-Head

Bigger by revenue
AMAL
AMAL
1.1× larger
AMAL
$85.2M
$77.6M
BIOX
Growing faster (revenue YoY)
AMAL
AMAL
+26.2% gap
AMAL
9.4%
-16.8%
BIOX
Faster 2-yr revenue CAGR
AMAL
AMAL
Annualised
AMAL
4.3%
-8.4%
BIOX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
AMAL
AMAL
BIOX
BIOX
Revenue
$85.2M
$77.6M
Net Profit
$-7.4M
Gross Margin
46.8%
Operating Margin
39.0%
9.3%
Net Margin
-9.6%
Revenue YoY
9.4%
-16.8%
Net Profit YoY
-20.2%
EPS (diluted)
$0.88
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMAL
AMAL
BIOX
BIOX
Q4 25
$85.2M
Q3 25
$85.6M
$77.6M
Q2 25
$80.9M
Q1 25
$77.0M
$60.6M
Q4 24
$77.9M
$98.8M
Q3 24
$81.0M
$93.3M
Q2 24
$78.5M
Q1 24
$78.3M
$84.0M
Net Profit
AMAL
AMAL
BIOX
BIOX
Q4 25
Q3 25
$26.8M
$-7.4M
Q2 25
$26.0M
Q1 25
$25.0M
$-1.6M
Q4 24
$605.2K
Q3 24
$27.9M
$-6.2M
Q2 24
$26.8M
Q1 24
$27.2M
$9.8M
Gross Margin
AMAL
AMAL
BIOX
BIOX
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Q1 24
50.8%
Operating Margin
AMAL
AMAL
BIOX
BIOX
Q4 25
39.0%
Q3 25
42.9%
9.3%
Q2 25
43.8%
Q1 25
45.1%
1.5%
Q4 24
42.4%
14.5%
Q3 24
47.2%
2.5%
Q2 24
45.6%
Q1 24
49.2%
15.7%
Net Margin
AMAL
AMAL
BIOX
BIOX
Q4 25
Q3 25
31.3%
-9.6%
Q2 25
32.1%
Q1 25
32.5%
-2.6%
Q4 24
0.6%
Q3 24
34.5%
-6.6%
Q2 24
34.1%
Q1 24
34.8%
11.6%
EPS (diluted)
AMAL
AMAL
BIOX
BIOX
Q4 25
$0.88
Q3 25
$0.88
$-0.12
Q2 25
$0.84
Q1 25
$0.81
$-0.02
Q4 24
$0.78
$0.00
Q3 24
$0.90
$-0.10
Q2 24
$0.87
Q1 24
$0.89
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMAL
AMAL
BIOX
BIOX
Cash + ST InvestmentsLiquidity on hand
$291.2M
$15.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$794.5M
$288.3M
Total Assets
$8.9B
$734.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMAL
AMAL
BIOX
BIOX
Q4 25
$291.2M
Q3 25
$115.5M
$15.5M
Q2 25
$171.1M
Q1 25
$65.7M
$38.5M
Q4 24
$60.7M
$29.2M
Q3 24
$149.2M
$32.3M
Q2 24
$58.0M
Q1 24
$155.2M
$16.4M
Stockholders' Equity
AMAL
AMAL
BIOX
BIOX
Q4 25
$794.5M
Q3 25
$775.6M
$288.3M
Q2 25
$754.0M
Q1 25
$736.0M
$345.0M
Q4 24
$707.7M
$346.3M
Q3 24
$698.2M
$346.0M
Q2 24
$646.0M
Q1 24
$616.8M
$348.5M
Total Assets
AMAL
AMAL
BIOX
BIOX
Q4 25
$8.9B
Q3 25
$8.7B
$734.9M
Q2 25
$8.6B
Q1 25
$8.3B
$798.2M
Q4 24
$8.3B
$835.2M
Q3 24
$8.4B
$827.3M
Q2 24
$8.3B
Q1 24
$8.1B
$836.1M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMAL
AMAL
BIOX
BIOX
Operating Cash FlowLast quarter
$135.8M
$14.4M
Free Cash FlowOCF − Capex
$134.4M
FCF MarginFCF / Revenue
157.8%
Capex IntensityCapex / Revenue
1.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$229.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMAL
AMAL
BIOX
BIOX
Q4 25
$135.8M
Q3 25
$39.5M
$14.4M
Q2 25
$24.9M
Q1 25
$34.2M
$23.3M
Q4 24
$124.1M
$-5.4M
Q3 24
$35.8M
$5.2M
Q2 24
$28.0M
Q1 24
$31.3M
$-17.4M
Free Cash Flow
AMAL
AMAL
BIOX
BIOX
Q4 25
$134.4M
Q3 25
$38.3M
Q2 25
$24.2M
Q1 25
$32.5M
Q4 24
$122.3M
Q3 24
$35.2M
Q2 24
$27.8M
Q1 24
$31.1M
FCF Margin
AMAL
AMAL
BIOX
BIOX
Q4 25
157.8%
Q3 25
44.7%
Q2 25
29.9%
Q1 25
42.2%
Q4 24
157.0%
Q3 24
43.4%
Q2 24
35.4%
Q1 24
39.7%
Capex Intensity
AMAL
AMAL
BIOX
BIOX
Q4 25
1.6%
Q3 25
1.4%
Q2 25
0.9%
Q1 25
2.3%
Q4 24
2.3%
Q3 24
0.7%
Q2 24
0.3%
Q1 24
0.3%
Cash Conversion
AMAL
AMAL
BIOX
BIOX
Q4 25
Q3 25
1.47×
Q2 25
0.96×
Q1 25
1.37×
Q4 24
-8.85×
Q3 24
1.28×
Q2 24
1.05×
Q1 24
1.15×
-1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons